(495b) Continuous Non-Fouling Anti-Solvent Crystallization of Rifapentine

Worldwide in 2022, tuberculosis is the second leading cause of death from an infectious disease after COVID-19 [1]. One important active pharmaceutical ingredient (API) for treating tuberculosis is rifapentine (RPT). The large demands on RPT medicines (e.g., tablets or inhalers) call for inexpensive scalable production of uniform RPT micro-crystals. However, RPT crystals from conventional batch production typically needs milling to reduce crystal size, and yield is not satisfying.[2] Further, RPT solids easily stick to surfaces, causing fouling in continuous processing. This talk presents a continuous anti-solvent crystallization process using simple set-up that addresses these issues, towards small uniform RPT crystals directly (without milling) at high yield, also with minimal fouling.

1. "Tuberculosis". World Health Organization (WHO). 2023. Retrieved April 8, 2024.

https://www.who.int/news-room/fact-sheets/detail/tuberculosis

2. Hadiwinoto, G. D.; Kwok, P. C. L.; Tong, H. H. Y.; Wong, S. N.; Chow, S. F.; Lakerveld, R. Integrated Continuous Plug-Flow Crystallization and Spray Drying of Pharmaceuticals for Dry Powder Inhalation. Ind. Eng. Chem. Res. 2019, 58 (36), 16843–16857.